CREB is a critical regulator of normal hematopoiesis and leukemogenesis by Cheng, Jerry C. et al.
doi:10.1182/blood-2007-04-083600 
Prepublished online Nov 1, 2007;
2008 111: 1182-1192
 
 
 
 
M. Sakamoto 
KathleenDeepa B. Shankar, Noriyuki Kasahara, Renata Stripecke, Ravi Bhatia, Elliot M. Landaw and 
Jerry C. Cheng, Kentaro Kinjo, Dejah R. Judelson, Jenny Chang, Winston S. Wu, Ingrid Schmid,
 
 leukemogenesis
CREB is a critical regulator of normal hematopoiesis and
 http://bloodjournal.hematologylibrary.org/cgi/content/full/111/3/1182
Updated information and services can be found at: 
 (2321 articles)Hematopoiesis 
 collections: BloodArticles on similar topics may be found in the following 
 http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at: 
 http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints
Information about ordering reprints may be found online at: 
 http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl
Information about subscriptions and ASH membership may be found online at: 
. Hematology; all rights reservedCopyright 2007 by The American Society of 
200, Washington DC 20036.
semimonthly by the American Society of Hematology, 1900 M St, NW, Suite 
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published
 
 
 
 
 personal use only.
For at CALIFORNIA INST TECH/MILLIKAN LIBRARY on February 1, 2008. www.bloodjournal.orgFrom 
HEMATOPOIESIS
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The cAMP-responsive element binding
protein (CREB) is a 43-kDa nuclear tran-
scription factor that regulates cell growth,
memory, and glucose homeostasis. We
showed previously that CREB is ampli-
fied in myeloid leukemia blasts and ex-
pressed at higher levels in leukemia stem
cells from patients with myeloid leuke-
mia. CREB transgenic mice develop my-
eloproliferative disease after 1 year, but
not leukemia, suggesting that CREB con-
tributes to but is not sufficient for leuke-
mogenesis. Here, we show that CREB is
most highly expressed in lineage nega-
tive hematopoietic stem cells (HSCs). To
understand the role of CREB in hemato-
poietic progenitors and leukemia cells,
we examined the effects of RNA interfer-
ence (RNAi) to knock down CREB expres-
sion in vitro and in vivo. Transduction of
primary HSCs or myeloid leukemia cells
with lentiviral CREB shRNAs resulted in
decreased proliferation of stem cells, cell-
cycle abnormalities, and inhibition of
CREB transcription. Mice that received
transplants of bone marrow transduced
with CREB shRNA had decreased commit-
ted progenitors compared with control
mice. Mice injected with Ba/F3 cells ex-
pressing either Bcr-Abl wild-type or T315I
mutation with CREB shRNA had delayed
leukemic infiltration by bioluminescence
imaging and prolonged median survival.
Our results suggest that CREB is critical
for normal myelopoiesis and leukemia
cell proliferation. (Blood. 2008;111:
1182-1192)
© 2008 by The American Society of Hematology
Introduction
Hematopoiesis is regulated by transcription factors that drive bone
marrow progenitor cells to proliferate and differentiate. Among the
nuclear factors that control gene transcription is a leucine zipper
transcription factor, cAMP-responsive element binding protein
(CREB), which activates genes that control metabolism, cell cycle,
signal transduction, and cell survival. CREB is a member of the
activating transcription factor (ATF)/CREB family of transcription
factors and requires phosphorylation of serine 133 for function.1,2
We demonstrated previously that CREB is a downstream target of
hematopoietic growth factor signaling activated by granulocyte-
macrophage–colony stimulating factor and interleukin-3.3-5 A role
for CREB in oncogenesis has been suggested by its overexpression
in the majority of bone marrow samples from patients with acute
leukemia.6 CREB is overexpressed at both the protein and mRNA
levels in leukemic blasts and in leukemia stem cells.7-9 Further-
more, CREB is amplified in blast cells from CREB-overexpressing
patients.6
We also demonstrated previously that CREB overexpression in
myeloid cells increases cell proliferation and survival. CREB
transgenic mice that overexpress CREB in the myeloid lineage
develop myeloproliferative disease/myelodysplastic syndrome but
not acute leukemia, suggesting that CREB contributes to myeloid
cell proliferation but is not sufficient for development of acute
leukemia. Bone marrow progenitors from CREB transgenic mice
demonstrate increased stem-cell self-renewal in replating assays
and increased sensitivity to hematopoietic growth factors.8 We
demonstrated that CREB overexpressing myeloid cells also have
increased expression of cyclin A associated with an increase in the
number of cells in S phase. Therefore, CREB seems to play a role
in hematopoietic stem cell (HSC) proliferation and survival
through its effects on cell-cycle regulation.
To understand the requirement of CREB in hematopoietic stem
cells and myeloid leukemia cells, we investigated the expression of
CREB in normal mouse and human HSCs and studied the effects of
CREB down-regulation on normal and leukemic cell proliferation
and maturation. In this article, we report that CREB is highly
expressed in normal lineage negative (lin) or uncommitted
hematopoietic progenitor cells and that inhibition of CREB expres-
sion using shRNAs resulted in decreased proliferation and differen-
tiation of normal and neoplastic hematopoietic cells in vitro and in
vivo, respectively. We also demonstrate by expression profiling,
potential mechanisms by which CREB may influence HSC fate.
Our results suggest that CREB plays a critical role in normal HSC
proliferation and leukemia progression.
Methods
Stem cells and preparation
Murine hematopoietic stem cells and progenitors were isolated from adult
C57BL6 mice as described previously.10-15 Mouse whole bone marrow cells
were divided into lin and lineage-positive (lin) cells using the mouse
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lineage cell-depletion kit of the magnetic activated cell-separation system
in combination with the auto MACS magnetic cell separator (Miltenyi
Biotec, Auburn, CA). The lin population was sorted either on a FACSDiVa
or a BD FACSAria cell sorter (BD Biosciences, Rockville, MD) into
hematopoietic stem cells and progenitors. The lin fraction was sorted into
mature hematopoietic cells, including T cells, B cells, granulocytes,
macrophages, and erythroid cells. Human cord blood cells were obtained
from Cambrex Charles City (Charles City, IA). Human lin cord blood cells
were separated into CD34 and CD34 cells using the human CD34
MicroBead kit in combination with the auto MACS separator. Human lin
CD34 cord blood cells were sorted by FACS into hematopoietic stem cells
and progenitors, and lin CD34 cord blood cells were sorted into mature
hematopoietic cells. Human peripheral blood stem cells (PBSCs) and bone
marrow cells were sorted by FACS into hematopoietic stem cells (CD34
CD38) and progenitors (CD34 CD38). Human lin PBSCs were sorted
by FACS into matured hematopoietic cells, including T cells (CD3),
B cells (CD19), NK cells (CD56), granulocytes/macrophages (CD14),
and erythroid cells (glycophorin-A). For cell-cycle experiments,
samples were stained according to a hypotonic propidium iodide
buffer–based protocol.16,17
Quantitative real-time and reverse transcription-polymerase
chain reaction
Total RNA was extracted from sorted cells (2-5  104 cells per sample)
using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. cDNA was synthesized using the Omniscript
Reverse Transcriptase Kit (Qiagen) or Transcriptor First Strand cDNA
Synthesis Kit (Roche Applied Science, Indianapolis, IN). To detect the
expression of transcription factors SCL, c-Mpl, Pu-1, Aiolos, and CEBP in
mouse HSC and progenitors, reverse transcription-polymerase chain reac-
tion (RT-PCR) was performed using primers and PCR conditions described
previously.18,19 Quantitative real-time PCR (q-PCR) was performed in
triplicate using the TaqMan probe system with CREB- and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)-specific probe and primers on an
ABI Prism 7700 sequence detection system (Applied Biosystems, Foster
City, CA) according to manufacturer’s instructions. CREB expression data
were standardized using GAPDH expression data. Primer sequences are
available upon request. For shRNA experiments, cells (5  106) were lysed
in TRIzol and stored at80°C before RNA extraction. RNA extraction was
performed according to a standard protocol supplied by the manufacturer
(Invitrogen, Carlsbad, CA), and pellets were resuspended in RNAse-free
water. The cDNA was transcribed with a Superscript RT III based-protocol.
DNAse treatment was not performed as a result of the selection of
intron-spanning primers. Quantitative real-time PCR was performed with
the SyberGreen reagent (Bio-Rad Laboratories, Hercules, CA) in triplicate
and analyzed by the standard curve method standardized to the housekeep-
ing gene -actin.20,21
shRNA sequence design and constructs
The CREB-specific shRNA sequences (CREB shRNA-1, CREB shRNA-2,
CREB shRNA-3) were selected and validated based on accepted parameters
established by Tuschl et al22-24 (http://www.rockefeller.edu/labheads/tuschl/
sirna.html). Sequence 2 was chosen for in vivo experiments based on
maximal gene inhibition. Controls included empty vector, luciferase
shRNA, and scrambled shRNA. shRNA sequences are CREB shRNA-1
(5-GCAAATGACAGTTCAAGCCC-3), shRNA-2 (5-GTACAGCTG-
GCTAACAATGG-3), shRNA-3 (5-GAGAGAGGTCCGTCTAATG-3),
Luciferase shRNA (5-GCCATTCTATCCTCTAGAGGA-3), and scramble
shRNA (5-GGACGAACCTGCTGAGATAT-3). Short-hairpin sequences
were synthesized as oligonucleotides and annealed according to standard
protocol. Annealed shRNAs were then subcloned into pSICO-R shRNA
vectors from the Jacks laboratory at MIT (http://web.mit.edu/ccr/labs/jacks/
index.html).25 The second generation SIN vector HIV-CSCG was used to
produce human shRNA vectors.26
Cell lines
The following human leukemia cell lines were transduced with shRNAs:
K562 (Iscove medium  10% fetal calf serum [FCS]), TF-1 (RPMI
medium  10% FCS  recombinant human granulocyte macrophage–
colony-stimulating factor [rhGM-CSF]), and MV-411 (Iscove me-
dium  10% FCS). Murine leukemia cell lines included Ba/F3-Bcr/Abl
wild type (RPMI medium  10% FCS) and Ba/F3-Bcr/Abl T315I (RPMI
medium  10% FCS). All leukemia cell lines express CREB. Cells were
cultured at 37°C, 5% CO2 and split every 3 to 4 days. Proliferation and
viability assays in Figure 4 were performed in triplicate by the trypan blue
exclusion method. Several transductions were performed for each shRNA
sequence to avoid clonal effects or selection. Each experiment was
performed within a week after transduction.
Western blot analysis
Boiling SDS-Laemmli method was used for all Western blot analyses.
Protein lysates were separated on a 10% SDS-polyacrylamide gel. Immuno-
blot was performed with anti-CREB (UBI, New York, NY), or -tubulin
antisera (Santa Cruz Biotechnology, Santa Cruz, CA) as described previ-
ously.8 All experiments were performed 3 times.
Lentiviral transduction of primary cells
One day before transduction, 7  105 cells were cultured in retronectin-
treated 96-well plates and pre-stimulated with appropriate cytokines; for
murine bone marrow, interleukin (IL)-3 (6 ng/mL), human IL-6
(10 ng/mL), and stem-cell factor (50 ng/mL) were used; for human
peripheral blood, IL-3 (10 ng/mL), IL-6 (10 ng/mL), stem-cell factor
(50 ng/mL), Flt-3 ligand (6 ng/mL), and thrombopoietin (6 ng/mL) were
used.27-30 All experiments were repeated at least 3 times. Human blood and
bone marrow cells were obtained with institutional review board consent
approved by the institution (UCLA IRB #98-09-036-21) in accordance with
the Declaration of Helsinki.
Colony-forming assays
Transduced and GFP-sorted hematopoietic cells (2  104 murine bone
marrow cells or 500 human CD34 cells) were plated in methylcellulose
(Stem Cells, Palo Alto, CA) containing a full complement of cytokines
(GM-CSF, IL-3, IL-6, stem-cell factor, erythropoietin [EPO]) or EPO alone
for blast forming unit–erythroid (BFU-E)/colony-forming unit–erythroid
(CFU-E) assays, and cultured for 21 days. Colony counts, cytospins, flow
cytometric analysis, and Western blot analysis were performed in triplicate
as described previously.8 Fluorescence-activated cell sorting (FACS) anti-
bodies used include CD150, CD135, Thy 1.1, CD117, Flk2, Sca-1, Mac-1,
Gr-1, CD3e, B220, and Ter119.
In vivo bioluminescence
SCID mice (The Jackson Laboratory, Bar Harbor, ME) were tail vein-
injected with 106 Ba/F3-Bcr/Abl T315I cells expressing luciferase that were
transduced with either CREB shRNA or a control scrambled shRNA. Mice
were followed over a period of approximately 4 weeks with serial
examinations for disease. Luciferin (15 g) was injected 10 to 15 minutes
before imaging and repeated every 7 days for a total of 2 weeks. Relative
intensity units for regions of interest were measured in triplicate and
averaged,31 with antilogs of log transform statistics used to estimate the
geometric mean ratio of intensities and its confidence interval. These
experiments were repeated twice. A similar approach was taken with
Ba/F3-Bcr/Abl wild-type cells expressing luciferase that were either not
transduced or transduced with CREB shRNA or a control, scrambled
shRNA. SCID mice were injected with 5  106 cells, monitored, and
images were acquired over 4 weeks as described previously in this
paragraph.
Apoptosis experiments
Standard Western blot analysis methods were applied to lysates made from
mouse bone marrow cells (106) that were transduced with CREB shRNA or
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control shRNA lentivirus. Blots were probed with anti-PARP antisera (Cell
Signaling Technology, Danvers, MA) to assess for cleavage fragments
confirmatory for apoptosis. In addition, flow cytometic methods were
performed using an allophycocyanin-tagged annexin-V monoclonal anti-
body and propidium iodide to assay for apoptotic cells.
Murine bone marrow transplantation
C57BL/6j CD45.2 mice were purchased from The Jackson Laboratory
and treated with prophylactic trimethoprim-sulfa therapy from four days
prior to transplant in water. Recipient mice were sublethally irradiated
on day 0 with a single dose of 9.5 Gy (950 rads) and subsequently
injected through the tail vein with 2  105 green fluorescent protein-
positive (GFP) bone marrow mononuclear cells from CD45.1 donors.
Donor cells were transduced as described previously (“Lentiviral
transduction of primary cells”) and positive transductants were FACS
sorted. Engraftment was monitored by serial eye bleeds and analysis of
bone marrow with complete blood counts and lineage-specific monoclo-
nal antibodies using flow cytometry.32-34 Antibodies used included
myeloid (Gr-1;Mac-1) and lymphoid (B220;CD3e). These experiments
were performed twice.
Results
To characterize the expression of CREB during adult mouse
hematopoiesis, we performed q-PCR on mRNA derived from
lin and lin murine bone marrow cells, and distinct lin and
lin subpopulations. CREB expression was higher (2.6-fold) in
the lin population than in the lin population (Figure 1A,
P  .01). Next, lin cells were further fractionated into HSCs
(Figure 1Ba), common myeloid progenitor (CMP; Figure 1Bb),
common lymphoid progenitor (CLP; Figure 1Be), granulocyte-
macrophage progenitor (GMP; Figure 1Bc), and megakaryocytic-
erythroid progenitor (MEP; Figure 1Bd) using their characteris-
tic cell surface antigen expression pattern and the gating and
cell-sorting strategy as outlined in Figure 1B. After sorting,
cDNAs from HSC, CMPs, CLPs, GMPs, and MEPs were
confirmed by expression of SCL, c-Mpl, PU.1, Aiolos, and
CCAAT/enhancer-binding protein  (C/EBP; Figure 1C). As
expected from the data we had obtained from lin cells, CREB
expression was higher in HSC, CMP, GMP, and MEP compared
with differentiated cells (Figure 1D). To further define CREB
expression in HSC, we examined the expression of CREB in
long-term HSCs (LT-HSCs), short-term HSCs (ST-HSCs), and
multipotent progenitors (MPPs; Figure 1E). CREB was slightly
higher in the MPP fraction compared with the LT-HSC and
ST-HSC populations, but this was not found to be statistically
significant (Figure 1E, P 	 .06).
To assess the mRNA CREB expression patterns in human
hematopoiesis, lin and lin cells were isolated from human cord
blood and peripheral blood stem cells and subjected to q-PCR.
CREB expression was higher (2-fold) in the lin population than in
the lin population for both cord and peripheral blood stem cells
(Figure 1F,G, respectively, P  .01). CREB expression in human
bone marrow cells was higher in CD34 CD38 cells than in
CD34 CD38 cells (Figure 1H,I). Our results demonstrate that the
lineage negative population consistently expressed higher levels of
CREB regardless of the stem-cell source.
We examined the requirement of CREB for normal hemato-
poiesis by transducing normal murine bone marrow cells with
CREB or control lentiviral shRNAs. Although 3 separate
shRNAs were tested in cell lines initially (Figure 4 and data not
Figure 1. CREB expression in mouse and human
hematopoietic progenitors. (A) CREB expression lev-
els in lin and lin cells as measured by q-PCR. CREB
expression was higher (2.6-fold) in the lin population
than the lin population (P 	 .01). (B) Gating strategy for
cell sorting of lin cells to isolate HSC (Ba), CMP (Bb),
GMP (Bc), MEP (Bd), CLP (Be), LT-HSC (Bf), ST-HSC
(Bg), and MPP (Bh). (C) cDNA from HSC CMPs, CLPs,
GMPs, and MEPs were confirmed by expression of SCL,
c-Mpl, Pu-1, Aiolos, and CEBP. (D) CREB expression
levels in HSC, CMP, GMP, MEP, and differentiated cells.
Compared with mature cells, CREB was 2.5- to 4-fold
higher in HSC, CMP, GMP, and MEP. (E) CREB expres-
sion in LT-HSC, ST-HSC, and MPP. CREB was slightly
higher (4- vs 3-fold) in the MPP fraction compared with
the LT-HSC and ST-HSC populations, but this was not
found to be statistically significant (P 	 .06). CREB ex-
pression in human lin and lin cells isolated from cord
blood (F) or peripheral blood (G) stem cells. CREB
expression was higher for both cell types in the lin
population than the lin population (P 	 .01). (H and I)
CREB expression in human bone marrow cells. CREB
was also expressed at higher levels in CD34 CD38
cells (b) than CD34 CD38 cells (a). All experiments
were performed in triplicate. Error bars represent SE.
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shown), shRNA sequence 2 was used to transduce primary bone
marrow cells because it was the most effective in down-
regulating CREB. Methylcellulose colony assays were per-
formed to assess qualitative and quantitative effects of CREB on
normal hematopoiesis in vitro (Figure 2A,B). Transduction
efficiency varied between 5% and 34%, as assessed by measur-
ing the GFP fraction by flow cytometry (data not shown). We
first analyzed CREB expression in primary mouse bone marrow
cells transduced with CREB shRNA lentivirus by Western blot
analysis and observed a significant inhibition of CREB expres-
sion (
80%) in CREB shRNA–transduced cells, compared with
control cells (Figure 2Ai). After 21 days, we detected a
statistically significant decrease (up to 5-fold) in the number of
GFP CFU-GM colonies with CREB shRNA-transduced mouse
bone marrow cells compared with vector or luciferase control
(Figure 2Aii). These colonies consisted of myeloid progenitor
cells that were mostly Mac-1 (Figure 2Aiii). The Mac-1
Gr-1 progenitor cell fraction, an immature population of cells,
was noted to be up to 4-fold higher in the CREB shRNA–
transduced cells compared with control cells.35 It is noteworthy
that there were fewer differentiated Mac-1 cells in the CREB
shRNA–transduced cells (30%) compared with vector control
(50%), suggesting that CREB is critical for both hematopoietic
cell proliferation and possibly terminal differentiation of mono-
cytes. There was no statistically significant difference in the
numbers of BFU-E or CFU-granulocyte/erythrocyte/monocyte
colonies in methylcellulose with CREB and scrambled shRNA-
transduced murine bone marrow progenitor cells. Likewise,
long-term culture-initiating cell assays showed no difference
between CREB and scrambled shRNA-transduced cells, suggest-
ing that although CREB is a critical regulator of early myelopoi-
esis, it does not appear to be necessary for hematopoietic stem-
cell proliferation and differentiation (data not shown).
The role of CREB in normal human hematopoietic cells was
studied by knocking down CREB through lentiviral transduction of
mobilized, CD34 normal peripheral blood mononuclear cells.
Efficiency of transduction was as high as 34% by GFP expression
(data not shown). CREB knockdown was 65% by Western blot
analysis after 21 days in methylcellulose (Figure 2Bi). We observed
a 3-fold decrease in CFU-GM colony formation in methylcellulose
with CREB shRNA–transduced cells compared with control cells
(P  .05; Figure 2Bii). Cytospin assays confirmed that CFU-GM
were in the form of immature myeloid cells (data not shown).
CREB shRNA–transduced stem cells had decreased numbers of
mature CD14 monocytes (Figure 2Biii). This suggests that CREB
down-regulation could be inhibiting terminal differentiation in
addition to proliferation and survival in vitro.
CREB has been previously demonstrated to enhance cell
proliferation and survival. To investigate the role of CREB in
apoptosis of primary bone marrow progenitor cells, we transduced
human and mouse bone marrow cells with CREB, scrambled, or
vector control shRNA lentivirus. Identical sequences were used as
described in Figure 2. In colony assays after 5 days, CREB
shRNA–transduced cells showed a decrease in the human CD34
fractions and an undetectable CD34 CD38 HSC population
compared with controls (Figure 3A and data not shown). For mouse
bone marrow transductions, a relatively higher proportion of
apoptotic cells in GFP CREB shRNA–transduced cells with an
increase in cells stained with annexin-V and propidium iodide (PI)
(Figure 2B; P  .05). However, the overall percentage of apoptotic
cells was less than 2%, suggesting that apoptosis occurs in a small
proportion of the total number of transduced cells. Primary mouse
BM progenitor cells transduced with CREB shRNA had increased
PARP cleavage compared with control cells (Figure 3C). There-
fore, our results suggest that CREB down-regulation in HSCs
inhibits proliferation and survival and to a lesser extent induces
apoptosis in vitro.
To study the requirement of CREB in normal hematopoiesis in
vivo, we also analyzed hematopoietic reconstitution of sublethally
irradiated B6/C7 CD45.2 mice at 5 and 12 weeks after infusion of
marrow progenitor cells from B6/C7 CD45.1 transduced with
CREB shRNA or scrambled shRNA lentivirus. We analyzed by
flow cytometry those cells that were GFP and CD45.1. Periph-
eral blood counts were comparable between both groups; however,
there was a statistically significant increase (4-fold) in myeloid
(Gr-1/Mac-1) progenitors and less dramatic increase in Mac-1
cells in the CREB shRNA group (Figure 4A and data not shown). At
12 weeks, very little difference was observed in lineage-specific
cells (Gr-1/Mac-1, Mac-1, and Gr-1, B220, and CD3e) or
hematopoietic stem cells (CD135, CD150, Thy1.1, Flk-2,
CD117, Sca-1, Ter119) from bone marrow between CREB
shRNA compared with scrambled shRNA (Figure 4B). These
results suggest that CREB could also be playing a role in regulating
myeloid differentiation of committed progenitor cells.
We next studied the effects of CREB down-regulation in
proliferation of myeloid leukemia cells. All cell lines had strong
basal CREB expression (Figure 5A). CREB was successfully
knocked-down in human (TF-1 and K562) myeloid leukemia cell
lines transduced with CREB shRNA at an efficiency of 45% to 92%
confirmed by Western blot analysis and q-PCR (Figure 5A,B). In
addition, phosphorylated CREB levels were lower in CREB
shRNA–transduced cells (Figure 5A). The growth and viability of
K562 and TF-1 leukemia cells were significantly decreased with
CREB shRNA–transduced cells compared with control cells (Fig-
ure 5C,i-iii). Furthermore, we did not see off-target effects indi-
cated by 2,5-oligoadenylate synthetase 1 (OAS-1) expression in
cells treated with interferon (Figure 5D).36 Multiple transductions
were performed with the different shRNA sequences to avoid the
effects of clonogenicity. We showed previously that overexpression
of CREB in myeloid leukemia cells resulted in increased cyclin A
promoter activity.8 To examine the effects of CREB shRNA on
CREB transcriptional activity, we transfected TF-1 cells with a
construct containing the cyclin A promoter with the cAMP-
responsive element and the luciferase reporter gene.8 A significant
decrease in cyclin A promoter activity was observed in cells
transduced with CREB shRNA compared with vector control
shRNA or untransduced cells (Figure 5E). We also analyzed the
effects of CREB shRNA on cell-cycle regulation in TF-1 cells
stimulated with GM-CSF for 12 hours after growth factor
starvation (Figure 5F). Our results demonstrated decreased
percentage of cells in S-phase and increased percentage of cells
in G1 and G2/M when CREB was down-regulated with 2
different CREB shRNA sequences.
To study the requirement of CREB during progression of
leukemia in vivo, Ba/F3 cells overexpressing Bcr-Abl wild type
or Bcr-Abl with the imatinib-resistant T315I mutation were
injected into SCID mice (Figures 6 and S1, available on the
Blood website; see the Supplemental Materials link at the top of
the online article.). These mice normally die within 21 days of
injection from leukemic infiltration of liver and spleen. The
Bcr-Abl–expressing Ba/F3 cells express CREB equal to the
Ba/F3 wild-type cells. The T315I mutant cell line was chosen
based on the 2-fold increased expression of CREB protein
compared with Bcr-Abl or untransduced Ba/F3 cells (Figure
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6A). Thus, we hypothesized that removing the CREB-dependent
component of Bcr-Abl T315I-induced transformation pathways
could affect leukemia progression. Transduction of Ba/F3
Bcr-Abl T315I cells resulted in an 80% decrease in CREB
protein and mRNA expression (Figure 6B,C). Six-week-old
SCID mice were injected with either 106 or 5  105 Ba/F3
Bcr-Abl wild-type or T315I transduced cells also expressing
luciferase (kindly provided to us by Neil Shah, University of
San Francisco, CA).37,38 Mice were analyzed after each luciferin
injection 15 minutes before imaging at days 7 and 14. A modest
effect on proliferation was also noted in vitro after CREB
knockdown in Ba/F3 T315I cells and analysis using trypan blue
Figure 2. CREB is critical for normal myelopoiesis in vitro. (A) (i) Western blot analysis demonstrating knockdown of CREB approaching 80% compared with control cells.
(ii) Total numbers of CFU-GM colonies after 21 days in methylcellulose for murine hematopoietic cells. (iii) Flow cytometric analysis of murine bone marrow transduced with
CREB shRNA or control lentivirus and sorted for GFP fraction, cultured in methylcellulose over 21 days. CREB knockdown cells had a lower fraction of mature granulocyte
and monocytes compared with control cells. (B) (i) Western blot analysis demonstrating knockdown of CREB up to 65% compared with control cells. (ii) Total number of
CFU-GM colonies after 21 days in methylcellulose for human peripheral blood stem cells. (iii) Flow cytometry analysis of transduced CD34 human peripheral blood stem cells
cultured in methylcellulose over 21 days. All experiments were performed in triplicate. Error bars in Aii,Bii represent SE.
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exclusion (Figure 6D). Bioluminescence imaging performed on
days 7 and 14 demonstrated a significant decrease in disease
burden in CREB knockdown mice with Ba/F3 Bcr-Abl T315I
cells compared with mice injected with scrambled shRNA
construct or Ba/F3 Bcr-Abl wild-type cells transduced with
control shRNA (Figures 6E,S1). This was confirmed by compar-
ing quantified bioluminescence intensities between comparable
regions of interest. For Bcr-Abl T315I-transduced cells, geomet-
ric mean bioluminescent intensity in control mice (scrambled
shRNA) was 3.4-fold larger than the knockdown group at day 7
and 4.9-fold at day 14 (95% confidence intervals, 2.1- to
Figure 4. CREB is critical for myelopoiesis in vivo. Bone marrow from CD45.1
mice transplanted into CD45.2 mice were analyzed with lineage-specific and
hematopoietic stem-cell markers using FACS analysis at 5 and 12 weeks after
transplantation. (A) Myeloid engraftment as measured by staining of bone marrow
cells from transplant-recipient mice at 5 weeks. (B) Myeloid engraftment as measured
by FACs staining of bone marrow cells at 12 weeks. At least 5 mice in each group
were analyzed. Experiments were performed in triplicate and repeated twice. Error
bars represent SE.
Figure 3. CREB shRNA induces apoptosis in HSCs and bone marrow progeni-
tor cells. (A) Transduced human peripheral blood cells plated in methylcellulose for
3 weeks and stained with monoclonal antibodies for CD34 and CD38 expression.
Cells were stained with PI to assess cell death. (B) Murine bone marrow cells were
transduced at a density of 106 cells/mL with lentivirus expressing CREB, scrambled,
or vector shRNA at a multiplicity of infection (MOI) of 100. After 2 days of culturing in
media containing cytokines (mIL-3, 10ng/mL; mSCF, 25 ng/mL; and hIL-6, 10 ng/mL),
cells were sorted using flow cytometry for GFP expression. Sorted calls were cultured
in cytokine containing media for 5 days and stained for annexin-V and PI. All
experiments were performed in triplicate. (C) Western blot analysis with lysates from
mouse BM cells (106) transduced with CREB shRNA, scrambled, luciferase, and
vector control lentivirus. Immunoblots were probed with anti-PARP or -tubulin
antisera. Error bars in panels A and B represent SE.
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Figure 5. CREB is essential for leukemia cell proliferation and survival. (A) Human (K562, TF-1) leukemia cells were transduced with a lentivirus expressing no
shRNA,1 CREB shRNA-1,2 CREB shRNA-2,3 or luciferase shRNA4 at a multiplicity of infection (MOI) of approximately 100. Wild-type cells5 were also used as a control.
Western blot analyses were performed with CREB, phospho-CREB, and -tubulin antisera. (B) Five micrograms of total RNA were extracted from transduced leukemia
cells, and q-PCR was performed to determine CREB expression. CREB was knocked down by up to 75% relative to control shRNA (vector) in human myeloid leukemia
cells. (C) Trypan blue exclusion method was performed in triplicate to assess growth and survival of transduced leukemia cells. CREB knocked-down cells
demonstrated diminished proliferation and viability 72 hours after transduction. (D) K562 cells were transduced and cultured for 48 hours before harvesting total RNA.
Parental K562 cells were cultured in the presence of interferon-2 (100 units/mL) for 48 hours as a positive control. Quantitative reverse transcription-PCR was
performed in triplicate with primers specific for CREB, actin, and OAS-1. (E) Luciferase reporter assays in human TF-1 leukemia cells transduced with CREB or control
shRNAs. Decreased transcriptional activity was observed in CREB knocked-down cells and repeated in triplicate. (F) Cell-cycle analysis of CREB knocked-down TF-1
cells after synchronization by serum starvation overnight and stimulated for 12 hours with GM-CSF revealed decreased percentage of cells in S-phase. Experiment was
performed in triplicate. Error bars in panels B-F represent SE.
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5.4-fold and 3.1- to 7.9-fold, respectively). Flow cytometric
analysis of splenocytes from injected mice confirmed the
presence of GFP cells (data not shown). Bioluminescence in
control cells was similarly elevated above knockdown using
unmutated Bcr-Abl transduced cells (Figure S1). Furthermore,
Kaplan-Meier analysis demonstrated a 3-day increase in median
survival time for mice injected with Ba/F3 T315I cells trans-
duced with CREB shRNA compared with scrambled shRNA at
both 5  105 cells injected (Figure 6F, P 	 .006) and 106 cells
(data not shown, P 	 .014 by logrank test). For mice injected
with 106 Ba/F3 Bcr-Abl wild-type cells, there was a 4-day
increase in median survival using CREB shRNA transduction
compared with scrambled shRNA (Figure S1, P 	 .09 by
Wilcoxon-Mann-Whitney test).
To understand possible downstream pathways mediating the
effects of CREB down-regulation, including cell-cycle abnormali-
ties, we sought to determine the levels of known CREB target
genes, cyclins D and A, which both affect cycle progression
Figure 6. CREB inhibits progression of leukemia in vivo. (A) Western blot analysis with CREB and tubulin antisera, demonstrating 2-fold increase in expression of CREB in
T315I mutant of Bcr-Abl in murine pro-B lymphocyte line (Ba/F3) compared with wild-type Ba/F3 cells. (B) Western blot analysis after lentiviral transduction with CREB shRNAs
demonstrating 90% inhibition. (C) Quantitative reverse transcription-PCR showing diminished CREB mRNA levels in transduced Ba/F3 T315I cells. (D) Trypan blue exclusion
method performed in triplicate shows diminished growth after transduction with CREB shRNA compared with empty vector. (E) Bioluminescence imaging of SCID mice injected
with 106 cells transduced with CREB shRNA or CREB scrambled shRNA lentivirus. Mice were imaged at days 7 and 14. Tumor burden is lower in CREB shRNA–injected mice.
(F) Kaplan-Meier survival analysis of mice injected with 5  105 cells showing longer survival with CREB knockdown (n 	 9) compared with scrambled shRNA (n 	 9). All
deaths were due to leukemia, except for a day 7 handling event in the scrambled group treated as a censored observation. Error bars in panels C and D represent SE.
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from G1 to S. Cyclin A also regulates the G2/M transition.1
Cyclin D is known to be a direct target of CREB by serial
analysis of gene expression (SAGE).39 Cyclin A has been
reported to be induced by CREB and is a direct target gene of
CREB.40 We observed a 5-fold decrease in cyclin D mRNA
expression in TF-1 and K562 cells transduced with CREB
shRNA compared with control cells (Figure 7A,B, P  .05).41
We also observed decreased cyclin A mRNA levels in CREB
shRNA–transduced TF-1 and K562 cells (Figure 7A,B, P  .05).
These results suggest that one possible reason for increased
numbers of cells in G1 and G2/M in CREB shRNA–transduced
leukemia cells is the inhibition of known target genes, such as
cell-cycle proteins, cyclin D, and cyclin A.
Discussion
We report that CREB can be successfully down-regulated through
lentiviral transduction in murine and human primary stem cells and
leukemia cell lines in vitro and in vivo. Our work demonstrates that
CREB is an important regulator of stem-cell proliferation, survival,
and differentiation during normal hematopoiesis. These observa-
tions are consistent with previous work suggesting that CREB is
critical for neuronal differentiation and survival.42 Our results are
also consistent with previous observations that when overex-
pressed, CREB acts as a proto-oncogene, resulting in increased
myeloid cell proliferation and myeloproliferative disease.8,43 In this
article, we show that inhibition of CREB expression leads to
abnormal proliferation, survival, and cell-cycle regulation of
normal HSCs and leukemia cells.
Analysis of CREB expression in normal HSC populations
support a role for CREB in uncommitted progenitors, because
lineage-negative stem cells have higher levels of CREB expression
compared with lineage-positive cells. In colony assays, CREB
shRNA had a more dramatic effect on murine HSC proliferation
than differentiation. Furthermore, there is an increase in less mature
Gr-1 /Mac-1 cells compared with differentiated Gr 1 or
Mac-1 cells. It is noteworthy that the effects of CREB shRNA, as
shown in colony assays, seemed to affect monocyte differentiation
more than granulocyte differentiation. Reduced proliferation of
human peripheral blood CD34 CD38 cells transduced with
CREB shRNA suggests the dependence of these cells on CREB.
CREB shRNA–transduced human peripheral blood CD34 CD38
HSCs also appeared to undergo apoptosis more readily than CD34
CD38 HSCs. Although CREB down-regulation resulted in in-
creased apoptosis, this does not seem to be a major factor in the role
of CREB in differentiation. Future studies will focus on analysis of
target genes and pathways that regulate hematopoietic differentia-
tion and proliferation downstream of CREB.
CREB also affected early engraftment of normal HSCs in
lethally irradiated mice. There were more immature myeloid cells
that were Gr-1/Mac-1 at 5 and 12 weeks after transplantation
(although more dramatic at 5 weeks), which is consistent with in
vitro colony assays. One explanation for this discrepancy is that the
CFU-GM colonies were counted after 2 weeks, whereas cells from
mice were analyzed after 5 and 12 weeks. The numbers of
terminally differentiated Gr-1 or Mac-1 cells were the same in
CREB and control shRNA-transduced HSCs at 5 and 12 weeks
after transplant. It is possible that other CREB family members (eg,
ATF2) are able to compensate for the decreased levels of CREB in
myeloid cells transduced with CREB shRNA. Furthermore, the
overall survival of mice that received transplants was not affected
by CREB shRNA. These results suggest that, in vivo, additional
mechanisms or redundant pathways could be responsible for
regulating HSCs under stress conditions and that CREB is not
required for early hematopoietic reconstitution.
CREB seems to regulate leukemia cell proliferation in vitro and
in vivo. Our ability to successfully suppress but not completely
inhibit the growth of several leukemia cell lines suggests that
CREB is one of several transcriptional factors or signal transduc-
tion pathways driving leukemic proliferation. CREB shRNA not
only affected proliferation, but also phosphorylation and transcrip-
tional activity of CREB in acute myeloid leukemia cells. Our
results demonstrate that CREB is necessary for maximal prolifera-
tion of myeloid leukemia cells in vitro and that CREB is probably
one but not the only critical target of signaling pathways regulating
growth of these cells. CREB may ultimately function in a role
analogous to C/EBP and PU.1, which have been shown to be
critical in early myeloid hematopoiesis and leukemia.44
We observed that CREB shRNA in vivo inhibited early leuke-
mic progression but did not significantly prolong maximal survival.
This may be due in part to the aggressive nature of Bcr-Abl wild
type and T315I mutation expressed in Ba/F3 cells injected into
SCID mice. Our results also suggest that CREB-dependent signal-
ing pathways are critical for Bcr-Abl T315I cell proliferation. The
Figure 7. Expression of cyclins A and D in leukemia cells. TF-1 (A) or K562
(B) myeloid leukemia cells were transduced with control and CREB shRNA lentivirus
and synchronized. At 12 hours, 5 g of total RNA was isolated for q-PCR by
SyberGreen method. Cyclin A1- and D1-specific primers were used, and expression
was normalized to the house keeping gene -actin. Experiments were performed in
triplicate. Error bars represent SE.
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time course of splenic and bone marrow infiltration was delayed
with CREB shRNA–transduced cells compared with control
cells. This suggests the possibility that CREB may be affecting
initial homing or engraftment of leukemia cells in the spleen and
bone marrow. However, the pattern of progression (ie, organs
infiltrated) appeared to be the same between CREB shRNA and
control cells. Alternatively, CREB may be slowing down the
initial growth of cells in mice, resulting in a longer latency
period for the leukemia to kill the mice. Experiments are in
progress to identify the pathways regulating leukemic progres-
sion of Bcr-Abl–expressing cells.
Our results demonstrated that CFU-GM was decreased in
mouse bone marrow progenitor colony assays transduced with
CREB shRNA. In the transplantation experiments, the mice had
increased Gr-1 /Mac-1 cells with CREB shRNA. Except for the
Mac-1 population in colony assays, CREB shRNA had minimal
effect on terminal differentiation of myeloid and lymphoid popula-
tions in vitro and in vivo (Figure 4 and data not shown). This could
reflect the contribution of CREB in monocyte differentiation, under
the specific culture conditions. The differences in the mouse bone
marrow colony assays at day 14 and knockdown of CREB did not
seem to affect hematopoietic reconstitution after 12 weeks and only
minimally induced apoptosis in progenitor cells. In contrast,
myeloid leukemia cells transduced with CREB shRNA had signifi-
cant inhibition in growth and increased apoptosis. Taken together,
our data suggest that CREB may be a viable target for leukemia
therapy.
CREB knockdown resulted in aberrant progression from G1 to S
and exit from G2/M to G1, suggesting a critical link between CREB
and the cell-cycle machinery in normal HSCs and leukemia cells.
Known CREB target genes include cyclin D1, which activates G1/S
cyclin-dependent kinases Cdk4 and Cdk6.39 Indeed, our results
demonstrated that CREB knockdown inhibited cyclin D1 expres-
sion, which could provide a mechanism by which cells arrest in G1
and fail to progress to S phase. Likewise, cyclin A1 has a CREB
binding site in its promoter, suggesting that cells could fail to
progress to S phase or exit from G2/M as a result of decreased
expression of cyclin A and failure to activate Cdk1 and Cdk2. It is
noteworthy that CREB transgenic mice develop myeloproliferative
disease with dysplastic myeloid cells in the spleen. CREB overex-
pression in myeloid leukemia cell lines and mouse spleens was
associated with increased cyclin A expression and increased
percentage of cells in S phase.9 Thus, it is possible that by being a
positive regulator of cyclins D and A, CREB overexpression could
lead to genomic instability and ultimately transformation. In this
article, we have shown that CREB down-regulation led to cell-
cycle arrest and effects opposite of those observed with CREB
overexpression. The key to understanding the role of CREB is to
elucidate the target genes that mediate its effects in proliferation
and survival. Future work will focus on the downstream pathways
regulating CREB function during normal and aberrant
hematopoiesis.
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